Company / SG&A Expense
NovaBay Pharmaceuticals, Inc. SG&A Expense History
FY2015-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$7.4M
FY2024
5-year range
$5.4M / $7.5M
FY2020-FY2024
Trend
+35.5%
vs FY2023
Sector context
#209 of 211
Health Care
What the data says
Among 211 Health Care companies, NovaBay Pharmaceuticals, Inc. is in the top 1% for sg&a expense. SG&A Expense has fluctuated over the past 10 years, ranging from $5M in FY2019 to $18M in FY2015.
Based on SEC 10-K filings.
$7M in FY2024 with a 5-year CAGR of +6.8%.
Remained stable around $7M over the past 2 years.
Health Care sector context is included.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- +0.6%
- 5-Year CAGR
- +6.8%
- 10-Year CAGR
- -
Sector benchmark
Top 1% in Health CareTop 1% of 211This company $7.4M Sector average $728.7M
▼
-99.0% below sector average
Key checks
Key Insights
- 5-year CAGR of +6.8%, indicating consistent growth.
- In FY2024, sg&a expense increased 35.5% year-over-year.
- Ranks #209 out of 211 companies in the Health Care sector.
- Peak sg&a expense was recorded in FY2015.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -5.51 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $7.4M | +35.5% |
| FY2023 | $5.4M | -27.3% |
| FY2022 | $7.5M | +3.4% |
| FY2021 | $7.2M | +22.0% |
| FY2020 | $5.9M | +11.7% |
| FY2019 | $5.3M | -8.9% |
| FY2018 | $5.8M | -32.5% |
| FY2017 | $8.6M | +19.4% |
| FY2016 | $7.2M | -60.0% |
| FY2015 | $18.1M | +128.0% |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026